{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T02:00:57Z","timestamp":1766023257525,"version":"3.48.0"},"reference-count":52,"publisher":"e-Century Publishing Corporation","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Cancer Res"],"DOI":"10.62347\/tytu4465","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T01:54:02Z","timestamp":1737510842000},"page":"84-98","source":"Crossref","is-referenced-by-count":1,"title":["Fedratinib and gandotinib induce apoptosis and enhance the efficacy of tyrosine kinase inhibitors in human mast cells"],"prefix":"10.62347","volume":"15","author":[{"given":"Alina","family":"Makeeva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Valent P, Akin C, Hartmann K, Alvarez-Twose I, Brockow K, Hermine O, Niedoszytko M, Schwaab J, Lyons JJ, Carter MC, Elberink HO, Butterfield JH, George TI, Greiner G, Ustun C, Bonadonna P, Sotlar K, Nilsson G, Jawhar M, Siebenhaar F, Broesby-Olsen S, Yavuz S, Zanotti R, Lange M, Nedoszytko B, Hoermann G, Castells M, Radia DH, Muñoz-Gonzalez JI, Sperr WR, Triggiani M, Kluin-Nelemans HC, Galli SJ, Schwartz LB, Reiter A, Orfao A, Gotlib J, Arock M, Horny HP and Metcalfe DD. Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal. Hemasphere 2021; 5: e646.","DOI":"10.1097\/HS9.0000000000000646"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, Chen W, Chen X, Chng WJ, Choi JK, Colmenero I, Coupland SE, Cross NCP, De Jong D, Elghetany MT, Takahashi E, Emile JF, Ferry J, Fogelstrand L, Fontenay M, Germing U, Gujral S, Haferlach T, Harrison C, Hodge JC, Hu S, Jansen JH, Kanagal-Shamanna R, Kantarjian HM, Kratz CP, Li XQ, Lim MS, Loeb K, Loghavi S, Marcogliese A, Meshinchi S, Michaels P, Naresh KN, Natkunam Y, Nejati R, Ott G, Padron E, Patel KP, Patkar N, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R, Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao W, Yeung C and Hochhaus A. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia 2022; 36: 1703-1719.","journal-title":"Leukemia"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"DA","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, Wang SA, Bagg A, Barbui T, Branford S, Bueso-Ramos CE, Cortes JE, Dal Cin P, DiNardo CD, Dombret H, Duncavage EJ, Ebert BL, Estey EH, Facchetti F, Foucar K, Gangat N, Gianelli U, Godley LA, Gökbuget N, Gotlib J, Hellström-Lindberg E, Hobbs GS, Hoffman R, Jabbour EJ, Kiladjian JJ, Larson RA, Le Beau MM, Loh ML, Löwenberg B, Macintyre E, Malcovati L, Mullighan CG, Niemeyer C, Odenike OM, Ogawa S, Orfao A, Papaemmanuil E, Passamonti F, Porkka K, Pui CH, Radich JP, Reiter A, Rozman M, Rudelius M, Savona MR, Schiffer CA, Schmitt-Graeff A, Shimamura A, Sierra J, Stock WA, Stone RM, Tallman MS, Thiele J, Tien HF, Tzankov A, Vannucchi AM, Vyas P, Wei AH, Weinberg OK, Wierzbowska A, Cazzola M, Döhner H and Tefferi A. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood 2022; 140: 1200-1228.","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1146\/annurev-pathmechdis-031521-042618","article-title":"New insights into the pathogenesis of mastocytosis: emerging concepts in diagnosis and therapy","volume":"18","author":"Valent","year":"2023","unstructured":"Valent P, Akin C, Sperr WR, Horny HP, Arock M, Metcalfe DD and Galli SJ. New insights into the pathogenesis of mastocytosis: emerging concepts in diagnosis and therapy. Annu Rev Pathol 2023; 18: 361-386.","journal-title":"Annu Rev Pathol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1002\/ajh.26962","article-title":"Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management","volume":"98","author":"Pardanani","year":"2023","unstructured":"Pardanani A. Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management. Am J Hematol 2023; 98: 1097-1116.","journal-title":"Am J Hematol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1172\/JCI116761","article-title":"Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product","volume":"92","author":"Furitsu","year":"1993","unstructured":"Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U, Sugahara H, Butterfield JH, Ashman LK, Kanayama Y, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 1993; 92: 1736-1744.","journal-title":"J Clin Invest"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1016\/j.jaip.2022.03.001","article-title":"Standards of genetic testing in the diagnosis and prognostication of systemic mastocytosis in 2022: recommendations of the EU-US cooperative group","volume":"10","author":"Hoermann","year":"2022","unstructured":"Hoermann G, Sotlar K, Jawhar M, Kristensen T, Bachelot G, Nedoszytko B, Carter MC, Horny HP, Bonadonna P, Sperr WR, Hartmann K, Brockow K, Lyons JJ, Kluin-Nelemans HC, Hermine O, Akin C, Broesby-Olsen S, Triggiani M, Butterfield JH, Schwaab J, Reiter A, Gotlib J, Metcalfe DD, George TI, Orfao A, Valent P and Arock M. Standards of genetic testing in the diagnosis and prognostication of systemic mastocytosis in 2022: recommendations of the EU-US cooperative group. J Allergy Clin Immunol Pract 2022; 10: 1953-1963.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1182\/blood.2021014612","article-title":"Avapritinib for advanced systemic mastocytosis","volume":"140","author":"Gotlib","year":"2022","unstructured":"Gotlib J, Reiter A and DeAngelo DJ. Avapritinib for advanced systemic mastocytosis. Blood 2022; 140: 1667-1673.","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Gotlib J, Castells M, Elberink HO, Siebenhaar F, Hartmann K, Broesby-Olsen S, George TI, Panse J, Alvarez-Twose I, Radia DH, Tashi T, Bulai Livideanu C, Sabato V, Heaney M, Van Daele P, Cerquozzi S, Dybedal I, Reiter A, Pongdee T, Barete S, Ustun C, Schwartz L, Ward BR, Schafhausen P, Vadas P, Bose P, DeAngelo DJ, Rein L, Vachhani P, Triggiani M, Bonadonna P, Rafferty M, Butt NM, Oh ST, Wortmann F, Ungerstedt J, Guilarte M, Taparia M, Kuykendall AT, Arana Yi C, Ogbogu P, Gaudy-Marqueste C, Mattsson M, Shomali W, Giannetti MP, Bidollari I, Lin HM, Sulllivan E, Mar B, Scherber R, Roche M, Akin C and Maurer M. Avapritinib versus placebo in indolent systemic mastocytosis. NEJM Evid 2023; 2: EVIDoa2200339.","DOI":"10.1056\/EVIDoa2200339"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","unstructured":"Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotlar K, Hermine O, Awan FT, Hexner E, Mauro MJ, Sternberg DW, Villeneuve M, Huntsman Labed A, Stanek EJ, Hartmann K, Horny HP, Valent P and Reiter A. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med 2016; 374: 2530-2541.","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Hartmann K, Gotlib J, Akin C, Hermine O, Awan FT, Hexner E, Mauro MJ, Menssen HD, Redhu S, Knoll S, Sotlar K, George TI, Horny HP, Valent P, Reiter A and Kluin-Nelemans HC. Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis. J Allergy Clin Immunol 2020; 146: 356-366, e354.","DOI":"10.1016\/j.jaci.2020.03.044"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"DeAngelo DJ, Pullarkat V, Piris-Villaespesa M, George TI, Patel JL, Ustun C, Bose P, Heaney ML, Pilla A, Massaro M, Exter B, Jolin HA, Mikhak Z and Tashi T. P1049: a phase 2 study of bezuclastinib (CGT9486), a novel, highly selective, potent KIT D816V inhibitor, in adults with advanced systemic mastocytosis (APEX): methods, baseline data, and early insights. Hemasphere 2022; 6 Suppl: 939-940.","DOI":"10.1097\/01.HS9.0000847064.38588.9b"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Tashi T, Hermine O, Castells M, Guilarte M, Sabato V, Maurer M, Panse J, Alvarez-Twose I, Cabral R, Bird R, Barete S, Bouillet L, Hermans M, Van Daele P, González-De-Olano D, Griffiths EA, Jurcic J, Dybedal I, Damaj GL, Schafhausen P, Elena C, Teh TC, Vachhani P, Labe C, Venugopal S, Kevin He, Muñoz-González J, Lampson B, Scherber R, Bose P, Grattan C, Pongdee T, George TI and Livideanu CB. Elenestinib, an investigational, next generation KIT D816V inhibitor, reduces mast cell burden, improves symptoms, and has a favorable safety profile in patients with indolent systemic mastocytosis: analysis of the harbor trial. Blood 2023; 142 Suppl 1: 76.","DOI":"10.1182\/blood-2023-188904"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1200\/JCO.2014.55.2018","article-title":"Hematopoietic stem-cell transplantation for advanced systemic mastocytosis","volume":"32","author":"Ustun","year":"2014","unstructured":"Ustun C, Reiter A, Scott BL, Nakamura R, Damaj G, Kreil S, Shanley R, Hogan WJ, Perales MA, Shore T, Baurmann H, Stuart R, Gruhn B, Doubek M, Hsu JW, Tholouli E, Gromke T, Godley LA, Pagano L, Gilman A, Wagner EM, Shwayder T, Bornhäuser M, Papadopoulos EB, Böhm A, Vercellotti G, Van Lint MT, Schmid C, Rabitsch W, Pullarkat V, Legrand F, Yakoub-Agha I, Saber W, Barrett J, Hermine O, Hagglund H, Sperr WR, Popat U, Alyea EP, Devine S, Deeg HJ, Weisdorf D, Akin C and Valent P. Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. J Clin Oncol 2014; 32: 3264-3274.","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.bbmt.2016.04.018","article-title":"Consensus opinion on allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis","volume":"22","author":"Ustun","year":"2016","unstructured":"Ustun C, Gotlib J, Popat U, Artz A, Litzow M, Reiter A, Nakamura R, Kluin-Nelemans HC, Verstovsek S, Gajewski J, Perales MA, George T, Shore T, Sperr W, Saber W, Kota V, Yavuz AS, Pullarkat V, Rogosheske J, Hogan W, Van Besien K, Hagglund H, Damaj G, Arock M, Horny HP, Metcalfe DD, Deeg HJ, Devine S, Weisdorf D, Akin C and Valent P. Consensus opinion on allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis. Biol Blood Marrow Transplant 2016; 22: 1348-1356.","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1182\/hematology.2022000368","article-title":"Available and emerging therapies for bona fide advanced systemic mastocytosis and primary eosinophilic neoplasms","volume":"2022","author":"Gotlib","year":"2022","unstructured":"Gotlib J. Available and emerging therapies for bona fide advanced systemic mastocytosis and primary eosinophilic neoplasms. Hematology Am Soc Hematol Educ Program 2022; 2022: 34-46.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1182\/blood.V98.5.1365","article-title":"Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant","volume":"98","author":"Chian","year":"2001","unstructured":"Chian R, Young S, Danilkovitch-Miagkova A, Rönnstrand L, Leonard E, Ferrao P, Ashman L and Linnekin D. Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant. Blood 2001; 98: 1365-1373.","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1182\/blood-2007-09-115477","article-title":"Oncogenic Kit controls neoplastic mast cell growth through a Stat5\/PI3-kinase signaling cascade","volume":"112","author":"Harir","year":"2008","unstructured":"Harir N, Boudot C, Friedbichler K, Sonneck K, Kondo R, Martin-Lannerée S, Kenner L, Kerenyi M, Yahiaoui S, Gouilleux-Gruart V, Gondry J, Bénit L, Dusanter-Fourt I, Lassoued K, Valent P, Moriggl R and Gouilleux F. Oncogenic Kit controls neoplastic mast cell growth through a Stat5\/PI3-kinase signaling cascade. Blood 2008; 112: 2463-2473.","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1182\/blood-2004-08-3247","article-title":"A novel NF-kappaB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors","volume":"105","author":"Tanaka","year":"2005","unstructured":"Tanaka A, Konno M, Muto S, Kambe N, Morii E, Nakahata T, Itai A and Matsuda H. A novel NF-kappaB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors. Blood 2005; 105: 2324-2331.","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"6803","DOI":"10.1182\/blood-2011-06-359984","article-title":"mTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells","volume":"118","author":"Smrz","year":"2011","unstructured":"Smrz D, Kim MS, Zhang S, Mock BA, Smrzová S, DuBois W, Simakova O, Maric I, Wilson TM, Metcalfe DD and Gilfillan AM. mTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells. Blood 2011; 118: 6803-6813.","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.2353\/ajpath.2009.080953","article-title":"Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V","volume":"175","author":"Baumgartner","year":"2009","unstructured":"Baumgartner C, Cerny-Reiterer S, Sonneck K, Mayerhofer M, Gleixner KV, Fritz R, Kerenyi M, Boudot C, Gouilleux F, Kornfeld JW, Sillaber C, Moriggl R and Valent P. Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V. Am J Pathol 2009; 175: 2416-2429.","journal-title":"Am J Pathol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1182\/blood-2018-02-833582","article-title":"CD44 is a RAS\/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis","volume":"132","author":"Mueller","year":"2018","unstructured":"Mueller N, Wicklein D, Eisenwort G, Jawhar M, Berger D, Stefanzl G, Greiner G, Boehm A, Kornauth C, Muellauer L, Sehner S, Hoermann G, Sperr WR, Staber PB, Jaeger U, Zuber J, Arock M, Schumacher U, Reiter A and Valent P. CD44 is a RAS\/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis. Blood 2018; 132: 1936-1950.","journal-title":"Blood"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s00018-003-2349-8","article-title":"Mast cells stimulated by membrane-bound, but not soluble, steel factor are dependent on phospholipase C activation","volume":"60","author":"NZ","year":"2003","unstructured":"Trieselmann NZ, Soboloff J and Berger SA. Mast cells stimulated by membrane-bound, but not soluble, steel factor are dependent on phospholipase C activation. Cell Mol Life Sci 2003; 60: 759-766.","journal-title":"Cell Mol Life Sci"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.4049\/jimmunol.177.5.3421","article-title":"Stat5 expression is required for IgE-mediated mast cell function","volume":"177","author":"Barnstein","year":"2006","unstructured":"Barnstein BO, Li G, Wang Z, Kennedy S, Chalfant C, Nakajima H, Bunting KD and Ryan JJ. Stat5 expression is required for IgE-mediated mast cell function. J Immunol 2006; 177: 3421-3426.","journal-title":"J Immunol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O&#x2019","year":"2015","unstructured":"O’Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB and Laurence A. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med 2015; 66: 311-328.","journal-title":"Annu Rev Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","unstructured":"Hu X, Li J, Fu M, Zhao X and Wang W. The JAK\/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther 2021; 6: 402.","journal-title":"Signal Transduct Target Ther"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1038\/leu.2010.109","article-title":"Inhibition of JAK-STAT signaling by TG101348: a novel mechanism for inhibition of KITD816V-dependent growth in mast cell leukemia cells","volume":"24","author":"Lasho","year":"2010","unstructured":"Lasho T, Tefferi A and Pardanani A. Inhibition of JAK-STAT signaling by TG101348: a novel mechanism for inhibition of KITD816V-dependent growth in mast cell leukemia cells. Leukemia 2010; 24: 1378-80.","journal-title":"Leukemia"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1111\/cea.13217","article-title":"The JAK1\/JAK2- inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release","volume":"48","author":"Hermans","year":"2018","unstructured":"Hermans MAW, Schrijver B, van Holten-Neelen CCPA, Gerth van Wijk R, van Hagen PM, van Daele PLA and Dik WA. The JAK1\/JAK2- inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release. Clin Exp Allergy 2018; 48: 1412-1420.","journal-title":"Clin Exp Allergy"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/0145-2126(88)90050-1","article-title":"Establishment of an immature mast cell line from a patient with mast cell leukemia","volume":"12","author":"Butterfield","year":"1988","unstructured":"Butterfield JH, Weiler D, Dewald G and Gleich GJ. Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res 1988; 12: 345-355.","journal-title":"Leuk Res"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1182\/blood-2013-10-534685","article-title":"A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection","volume":"124","author":"Saleh","year":"2014","unstructured":"Saleh R, Wedeh G, Herrmann H, Bibi S, Cerny-Reiterer S, Sadovnik I, Blatt K, Hadzijusufovic E, Jeanningros S, Blanc C, Legarff-Tavernier M, Chapiro E, Nguyen-Khac F, Subra F, Bonnemye P, Dubreuil P, Desplat V, Merle-Béral H, Willmann M, Rülicke T, Valent P and Arock M. A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection. Blood 2014; 124: 111-120.","journal-title":"Blood"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1096\/fj.14-250894","article-title":"CD52 is a molecular target in advanced systemic mastocytosis","volume":"28","author":"Hoermann","year":"2014","unstructured":"Hoermann G, Blatt K, Greiner G, Putz EM, Berger A, Herrmann H, Cerny-Reiterer S, Gleixner KV, Walz C, Hoetzenecker K, Müllauer L, Reiter A, Sotlar K, Sexl V, Valent P and Mayerhofer M. CD52 is a molecular target in advanced systemic mastocytosis. FASEB J 2014; 28: 3540-3551.","journal-title":"FASEB J"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1084\/jem.108.2.259","article-title":"Chromosomal constitution of cells in tissue culture","volume":"108","author":"Tjio","year":"1958","unstructured":"Tjio JH and Puck TT. Genetics of somatic mammalian cells. II. Chromosomal constitution of cells in tissue culture. J Exp Med 1958; 108: 259-68.","journal-title":"J Exp Med"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1038\/s41596-019-0288-6","article-title":"Rapid identification of human mast cell degranulation regulators using functional genomics coupled to high-resolution confocal microscopy","volume":"15","author":"Folkerts","year":"2020","unstructured":"Folkerts J, Gaudenzio N, Maurer M, Hendriks RW, Stadhouders R, Tam SY and Galli SJ. Rapid identification of human mast cell degranulation regulators using functional genomics coupled to high-resolution confocal microscopy. Nat Protoc 2020; 15: 1285-1310.","journal-title":"Nat Protoc"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"27","DOI":"10.20517\/2394-4722.2020.58","article-title":"Targeting the JAK\/STAT pathway in solid tumors","volume":"6","author":"Qureshy","year":"2020","unstructured":"Qureshy Z, Johnson DE and Grandis JR. Targeting the JAK\/STAT pathway in solid tumors. J Cancer Metastasis Treat 2020; 6: 27.","journal-title":"J Cancer Metastasis Treat"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Mathew D, Marmarelis ME, Foley C, Bauml JM, Ye D, Ghinnagow R, Ngiow SF, Klapholz M, Jun S, Zhang Z, Zorc R, Davis CW, Diehn M, Giles JR, Huang AC, Hwang WT, Zhang NR, Schoenfeld AJ, Carpenter EL, Langer CJ, Wherry EJ and Minn AJ. Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients. Science 2024; 384: eadf1329.","DOI":"10.1126\/science.adf1329"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ccr.2014.05.019","article-title":"Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells","volume":"26","author":"Lee","year":"2014","unstructured":"Lee HJ, Zhuang G, Cao Y, Du P, Kim HJ and Settleman J. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell 2014; 26: 207-221.","journal-title":"Cancer Cell"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1093\/ibd\/izy364","article-title":"A JAK1 selective kinase inhibitor and tofacitinib affect macrophage activation and function","volume":"25","author":"Vries LCS","year":"2019","unstructured":"De Vries LCS, Duarte JM, De Krijger M, Welting O, Van Hamersveld PHP, Van Leeuwen-Hilbers FWM, Moerland PD, Jongejan A, D’Haens GR, De Jonge WJ and Wildenberg ME. A JAK1 selective kinase inhibitor and tofacitinib affect macrophage activation and function. Inflamm Bowel Dis 2019; 25: 647-660.","journal-title":"Inflamm Bowel Dis"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1111\/all.15322","article-title":"JAK1\/2 inhibitor but not IL-4 receptor alpha antibody suppresses allergen-mediated activation of human basophils in vitro","volume":"77","author":"Peng","year":"2022","unstructured":"Peng W, Benfadal S, Yu C, Wenzel J, Oldenburg J and Novak N. JAK1\/2 inhibitor but not IL-4 receptor alpha antibody suppresses allergen-mediated activation of human basophils in vitro. Allergy 2022; 77: 2253-2256.","journal-title":"Allergy"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3324\/haematol.2018.212126","article-title":"Oncogenic D816V-KIT signaling in mast cells causes persistent IL-6 production","volume":"105","author":"Tob&#xED","year":"2020","unstructured":"Tobío A, Bandara G, Morris DA, Kim DK, O’Connell MP, Komarow HD, Carter MC, Smrz D, Metcalfe DD and Olivera A. Oncogenic D816V-KIT signaling in mast cells causes persistent IL-6 production. Haematologica 2020; 105: 124-135.","journal-title":"Haematologica"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/vco.12311","article-title":"The JAK2\/STAT5 signaling pathway as a potential therapeutic target in canine mastocytoma","volume":"16","author":"Keller","year":"2018","unstructured":"Keller A, Wingelhofer B, Peter B, Bauer K, Berger D, Gamperl S, Reifinger M, Cerny-Reiterer S, Moriggl R, Willmann M, Valent P and Hadzijusufovic E. The JAK2\/STAT5 signaling pathway as a potential therapeutic target in canine mastocytoma. Vet Comp Oncol 2018; 16: 55-68.","journal-title":"Vet Comp Oncol"},{"key":"ref40","unstructured":"Pérez-Pons A, Jara-Acevedo M, Henriques A, Navarro-Navarro P, García-Montero AC, Álvarez-Twose I, Pedreira CE, Sánchez-Muñoz L, Damasceno D, Caldas C, Muñoz-González JI, Matito A, Flores-Montero J, González-López O, Criado I, Mayado A and Orfao A. Altered innate immune profile in blood of systemic mastocytosis patients. Clin Transl Allergy 2022; 12: e12167."},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Hermans MAW, Heeringa JJ, Swagemakers SGA, Schrijver B, van Daele PLA, van der Spek PJ, van Hagen PM, van Zelm MC and Dik WA. Altered leukocyte subsets and immune proteome indicate proinflammatory mechanisms in mastocytosis. J Allergy Clin Immunol 2022; 150: 146-156, e110.","DOI":"10.1016\/j.jaci.2021.12.786"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/leu.2015.176","article-title":"Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression","volume":"30","author":"Mayado","year":"2016","unstructured":"Mayado A, Teodosio C, Garcia-Montero AC, Matito A, Rodriguez-Caballero A, Morgado JM, Muñiz C, Jara-Acevedo M, Álvarez-Twose I, Sanchez-Muñoz L, Matarraz S, Caldas C, Muñoz-González JI, Escribano L and Orfao A. Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression. Leukemia 2016; 30: 124-130.","journal-title":"Leukemia"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1182\/blood.2023020515","article-title":"TNF alpha promotes clonal dominance of KIT D816V+ cells in mastocytosis: role of survivin and impact on prognosis","volume":"143","author":"Greiner","year":"2024","unstructured":"Greiner G, Witzeneder N, Klein K, Tangermann S, Kodajova P, Jaeger E, Ratzinger F, Gerner MC, Jawhar M, Baumgartner S, Fruehwirth K, Schmetterer KG, Zuber J, Gleixner KV, Mayerhofer M, Schwarzinger I, Simonitsch-Klupp I, Esterbauer H, Baer C, Walter W, Meggendorfer M, Strassl R, Haferlach T, Hartmann K, Kenner L, Sperr WR, Reiter A, Sexl V, Arock M, Valent P and Hoermann G. TNF alpha promotes clonal dominance of KIT D816V+ cells in mastocytosis: role of survivin and impact on prognosis. Blood 2024; 143: 1006-1017.","journal-title":"Blood"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Marotte H, Tsou PS, Fedorova T, Pinney AJ, Lewis B and Koch AE. Blocking the janus-activated kinase pathway reduces tumor necrosis factor alpha-induced interleukin-18 bioactivity by caspase-1 inhibition. Arthritis Res Ther 2014; 16: R102.","DOI":"10.1186\/ar4551"},{"key":"ref45","unstructured":"Sandersa NL, Venkateshaiah SU, Manohar M, Verma AK, Kandikattu HK and Mishra A. Interleukin-18 has an important role in differentiation and maturation of mucosal mast cells. J Mucosal Immunol Res 2018; 2: 109."},{"key":"ref46","doi-asserted-by":"publisher","first-page":"5246","DOI":"10.1182\/blood.V122.21.5246.5246","article-title":"Activity of a JAK1\/JAK2 inhibitor in a patient with KIT-mutated systemic mastocytosis (SM) associated with myelofibrosis","volume":"122","author":"Santos","year":"2013","unstructured":"Santos FPS, Helman R, Pereira WO, Puga RD, Nakashima SS, Bello IC, Diniz MS, Hamerschlak N and Campregher PV. Activity of a JAK1\/JAK2 inhibitor in a patient with KIT-mutated systemic mastocytosis (SM) associated with myelofibrosis. Blood 2013; 122: 5246-5246.","journal-title":"Blood"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1111\/bjh.13951","article-title":"Beneficial effects of JAK inhibitor therapy in systemic mastocytosis","volume":"176","author":"Dowse","year":"2017","unstructured":"Dowse R, Ibrahim M, McLornan DP, Moonim MT, Harrison CN and Radia DH. Beneficial effects of JAK inhibitor therapy in systemic mastocytosis. Br J Haematol 2017; 176: 324-327.","journal-title":"Br J Haematol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jdin.2021.11.001","article-title":"A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): an interim 24-week analysis","volume":"6","author":"Katoh","year":"2022","unstructured":"Katoh N, Ohya Y, Murota H, Ikeda M, Hu X, Ikeda K, Liu J, Sasaki T, Chu AD, Teixeira HD and Saeki H. A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): an interim 24-week analysis. JAAD Int 2022; 6: 27-36.","journal-title":"JAAD Int"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","article-title":"Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial","volume":"156","author":"Silverberg","year":"2020","unstructured":"Silverberg JI, Simpson EL, Thyssen JP, Gooderham M, Chan G, Feeney C, Biswas P, Valdez H, DiBonaventura M, Nduaka C and Rojo R. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol 2020; 156: 863-873.","journal-title":"JAMA Dermatol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.jaad.2022.09.060","article-title":"Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: results from two phase 3 studies","volume":"88","author":"Papp","year":"2023","unstructured":"Papp K, Szepietowski JC, Kircik L, Toth D, Eichenfield LF, Forman SB, Kuligowski ME, Kallender H, Sun K, Ren H and Simpson EL. Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: results from two phase 3 studies. J Am Acad Dermatol 2023; 88: 1008-1016.","journal-title":"J Am Acad Dermatol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","article-title":"Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo","volume":"387","author":"Rosmarin","year":"2022","unstructured":"Rosmarin D, Passeron T, Pandya AG, Grimes P, Harris JE, Desai SR, Lebwohl M, Ruer-Mulard M, Seneschal J, Wolkerstorfer A, Kornacki D, Sun K, Butler K and Ezzedine K; TRuE-V Study Group. Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo. N Engl J Med 2022; 387: 1445-1455.","journal-title":"N Engl J Med"}],"container-title":["American Journal of Cancer Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajcr\/15\/1\/ajcr0161390.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:55:58Z","timestamp":1766022958000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajcr\/15\/1\/ajcr0161390.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/tytu4465","relation":{},"ISSN":["2156-6976"],"issn-type":[{"type":"electronic","value":"2156-6976"}],"subject":[],"published":{"date-parts":[[2025]]}}}